Extracellular vesicles derived from mesenchymal stem cells eased the signs and symptoms of pulmonary hypertension (PH) in a rat model of bronchopulmonary dysplasia (BPD), a study shows. BPD is one of the most common complications in prematurely born infants who need supplemental oxygen and is marked by airway damage…
News
Treatment with Adempas (riociguat) improved blood flow measurements in people with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF) in a clinical trial. Researchers say that further study is needed to determine the effect of Adempas on clinical outcomes like exercise capacity. The study, “…
The PAH Today National Broadcast Series, created to help adults and their caregivers in the U.S. cope with pulmonary arterial hypertension (PAH), returns with two discussions for this year. Presented by the PAH Initiative and sponsored by United Therapeutics, the series offers views on contemporary approaches to managing…
Diagnostic testing plays an important role in guiding changes in treatment for children with pulmonary arterial hypertension (PAH), suggesting that virtual healthcare visits may not be an adequate substitute for in-person testing for many children with the disease. That’s according to the study, “Factors Determining Change in Treatment for…
Mixed venous oxygen tension (PvO2) — a measure for tissue oxygenation — is a significant predictor of outcomes in pulmonary hypertension (PH), a study suggested. Specifically, lower PvO2 was significantly associated with poor outcomes in people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH),…
Elevated metabolites of the kynurenine pathway in the bloodstream of people with pulmonary arterial hypertension (PAH) when they’re diagnosed predicted disease severity, their response to therapy, and survival, a study discovered. Activation of the kynurenine pathway, related to vitamin B3 production, was found to be linked to…
Nearly a third (29.7%) of COVID-19 patients showed signs of pulmonary hypertension (PH) on an echocardiogram — a scan of heart movement — according to a study in the Netherlands. While mortality rates were significantly higher among those with suspected PH than those without it, follow-up tests suggested that…
Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with pulmonary arterial hypertension (PAH) in the Phase 3 INSPIRE clinical trial. The therapy was preferred by nearly all trial participants who switched to it from Tyvaso, an older inhaled…
When done during pregnancy, an echocardiogram — a noninvasive measurement of heart function that uses sound waves — may help doctors predict pulmonary hypertension in newborns, a study in China suggests. An echocardiogram can show how well the heart’s right ventricle, one of its bottom pumping chambers, will push…
More than half of people with pulmonary arterial hypertension (PAH) who start daily treatment with oral Opsumit (macitentan) are expected to still be alive after nine years on the therapy, according to a new analysis of data from the SERAPHIN clinical trial and its open-label extension. “These analyses…
Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH) in a Phase 3 clinical trial, although its use did not significantly affect measures of physical abilities. Full trial results are in “Selexipag for the treatment of…
Among people with chronic thromboembolic pulmonary hypertension (CTEPH), risk assessments and treatment patterns prior to surgical procedures do not predict outcomes after surgery, a new study from Sweden shows. The results suggest that most CTEPH patients who don’t undergo surgery remain in the same risk category for at least…
